

June 3, 1969

Dr. Allen P. Borger
Associate Director
Chas. Pfizer & Co., Inc.
Groton, Connecticut 06340

Dear Allen,

Enclosed is a proposed analysis of CP 14,368. Instead of the usual two-step, I am proposing a three-step study in which the first few subjects will be studied in an open situation in order to determine dose - time relationships. A defined open study will give us the approximate classification and this will follow Dr. Itil's recommendations. If we are successful with both these steps, we will have the necessary information to do a definitive classification study.

Dr. Itil was most helpful.

If this program meets with your approval I would appreciate a supply of 50 capsules (tablets) of 50 mg CP 14,368 and an equal number of placebo.

The study can be begun as soon as supplies are made available.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp